Evidence map›Paper›PMID 27412386›Full record

Trial reportBMC cancer2016

Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.

James M Cleary, Harvey J Mamon, Jackie Szymonifka, Raphael Bueno, Noah Choi, Dean M Donahue, Panos M Fidias, Henning A Gaissert, Michael T Jaklitsch, Matthew H Kulke and 7 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00137852 (Phase II Trial of Cisplatin, CPT-11, Celecoxib), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00137852 phase2completednot on this map

Phase II Trial of Cisplatin, CPT-11, Celecoxib (PCC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer

TypeinterventionalSponsorDana-Farber Cancer InstituteRan2002 to 2017Enrolled35ConditionsEsophageal CancerArmsCisplatin, Irinotecan, Celecoxib, Radiation Therapy, Esophagectomy
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. The role of lipid metabolism in cancer radioresistance.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  3. Review
  4. Article
  5. Article
  6. Oncotarget · 2017
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

James M ClearyCenter for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.
Harvey J MamonCenter for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.
Jackie SzymonifkaCenter for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.
Raphael BuenoCenter for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.
Noah ChoiMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Dean M DonahueMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Panos M FidiasMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Henning A GaissertMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Michael T JaklitschCenter for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.
Matthew H KulkeCenter for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.
Thomas P LynchMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Steven J MentzerCenter for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.
Jeffrey A MeyerhardtCenter for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.
Richard S SwansonCenter for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.
John WainMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Charles S FuchsCenter for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.
Peter C EnzingerCenter for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA. peter_enzinger@dfci.harvard.edu.
Dana-Farber Brigham Cancer Center · USDana-Farber Cancer Institute · USHarvard University · USMassachusetts General Hospital · US

Funding

Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2M
NCI NIH HHS P50 CA127003
6 · The paper itself

Abstract

backgroundPatients with locally advanced esophageal cancer who are treated with trimodality therapy have a high recurrence rate. Preclinical evidence suggests that inhibition of cyclooxygenase 2 (COX2) increases the effectiveness of chemoradiation, and observational studies in humans suggest that COX-2 inhibition may reduce esophageal cancer risk. This trial tested the safety and efficacy of combining a COX2 inhibitor, celecoxib, with neoadjuvant irinotecan/cisplatin chemoradiation.

methodsThis single arm phase 2 trial combined irinotecan, cisplatin, and celecoxib with concurrent radiation therapy. Patients with stage IIA-IVA esophageal cancer received weekly cisplatin 30 mg/m(2) plus irinotecan 65 mg/m(2) on weeks 1, 2, 4, and 5 concurrently with 5040 cGy of radiation therapy. Celecoxib 400 mg was taken orally twice daily during chemoradiation, up to 1 week before surgery, and for 6 months following surgery.

resultsForty patients were enrolled with stage IIa (30 %), stage IIb (20 %), stage III (22.5 %), and stage IVA (27.5 %) esophageal or gastroesophageal junction cancer (AJCC, 5th Edition). During chemoradiation, grade 3-4 treatment-related toxicity included dysphagia (20 %), anorexia (17.5 %), dehydration (17.5 %), nausea (15 %), neutropenia (12.5 %), diarrhea (10 %), fatigue (7.5 %), and febrile neutropenia (7.5 %). The pathological complete response rate was 32.5 %. The median progression free survival was 15.7 months and the median overall survival was 34.7 months. 15 % (n = 6) of patients treated on this study developed brain metastases.

conclusionsThe addition of celecoxib to neoadjuvant cisplatin-irinotecan chemoradiation was tolerable; however, overall survival appeared comparable to prior studies using neoadjuvant cisplatin-irinotecan chemoradiation alone. Further studies adding celecoxib to neoadjuvant chemoradiation in esophageal cancer are not warranted.

trial registrationClinicaltrials.gov: NCT00137852 , registered August 29, 2005.

Indexed as

Administration, OralAdultAgedAnorexiaAntineoplastic Combined Chemotherapy ProtocolsCamptothecinCelecoxibChemoradiotherapyChemotherapy-Induced Febrile NeutropeniaCisplatinCyclooxygenase 2 InhibitorsDeglutition DisordersDisease-Free SurvivalDrug Administration ScheduleEsophageal NeoplasmsEsophagogastric JunctionCamptothecinCelecoxibCisplatinCyclooxygenase 2 InhibitorsIrinotecanChemoradiationCyclooxygenase 2 inhibitionEsophageal cancerNeoadjuvant therapy

Identifiers

PMID27412386
PMCPMC4944495
OpenAlexW2467654854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.